Sana Biotechnology, a company that develops platforms to replace or repair cells in our bodies, wrapped an upsized IPO at $588 million.
Morgan Stanley, Goldman Sachs Group, JPMorgan and BofA Securities were the bookrunners for the deal.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.61 |
|---|---|
| 52-week range | $2.29 - $12.00 |
| 50-day moving average | $3.77 |
| 200-day moving average | $6.44 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.40 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.35 from 2024-11-21
| 1 week (2024-11-15) | -2.89% |
|---|---|
| 1 month (2024-10-23) | -37.99% |
| 3 months (2024-08-22) | -58.84% |
| 6 months (2024-05-22) | -71.55% |
| 1 year (2023-11-22) | -44.71% |
|---|---|
| 2 years (2022-11-22) | -50.21% |
| 3 years (2021-11-22) | 19 |
| 5 years (2019-11-19) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -31.15% |
| Return on equity TTM | -92.9% |
| Profit margin | 0% |
| Book value | $1.31 |
| Market Capitalization | $524.7 million |
TTM: trailing 12 months
We're not expecting Sana Biotechnology Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Sana Biotechnology Inc's shares have ranged in value from as little as $2.29 up to $12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sana Biotechnology Inc's is 1.442. This would suggest that Sana Biotechnology Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Sana Biotechnology Inc's beta into context you can compare it against those of similar companies.
Sana Biotechnology, Inc. , a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.